COVID-19: What to do after suboptimal immune response to SARS-CoV-2 vaccination in patients undergoing thoracic organ transplantation? Evaluation of potential strategies to detect and improve immunogenicity in the context of an individualised intensified vaccination approach.

COVID-19: What to do after suboptimal immune response to SARS-CoV-2 vaccination in patients undergoing thoracic organ transplantation? Evaluation of potential strategies to detect and improve immunogenicity in the context of an individualised intensified vaccination approach. - HTx-CovOM

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00030734

Enrollment

300

Registered

2022-11-17

Start date

2022-11-16

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Z94.1

Interventions

Group 1: Within the framework of the project, patients will be offered the opportunity to have their SARS-Cov2 antibodies determined before and 4 weeks after the renewed booster dose with a vaccine ad

the blood samples should be taken by the general practitioner as part of routine blood sampling. After use for the antibody determination, reserve samples are taken from the serum tubes and frozen fo

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Men and women after thoracic organ transplantation with a minimum age of 18 years who have received at least the triple vaccination against SARS-CoV-2; Further booster vaccination is planned in the near future but has not yet been given; Precondition: Present signed and dated study consent.

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
The aim is to develop a strategy for an individualised intensified vaccination concept depending on humoral and cellular response to at least triple vaccination in patients after organ transplantation. For this purpose, the IgG anti-SARS-CoV-2 antibody titer will be determined before and 4 weeks after booster vaccination.	—

Countries

Germany

Contacts

Public ContactHeike Windhagen

Herz- und Diabeteszentrum NRW, Klinik für Thorax- u. Kardiovaskularchirurgie, Universitätsklinikum der Ruhr Universität Bochum

hwindhagen@hdz-nrw.de05731-97-1907

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026